Introduction
Herpes simplex virus, despite years of investigation, has remained a formidable opponent for the ophthalmologist and affected patient.It is known for causing myriad of corneal manifestations from classic dendritic epithelial disease to fulminant necrotizing stromal keratitis leading to corneal perforation. [1] With the global incidence of roughly 1.5 million, including 40,000 new cases of severe monocular visual impairment or blindness each year HSV keratitis is a leading cause of corneal opacification and an important indication for penetrating keratoplasty. [2, 3] The virus is enveloped with a cuboidal capsule ,has linear double-stranded DNA structure and is classified as an α -member of the Herpesviridae family . Primary infection, without previous viral exposure, usually occurs in childhood and is spread by droplet transmission, or by direct inoculation. Mostly they are subclinical or cause only mild fever, malaise and upper respiratory tract symptoms. Blepharitis and follicular conjunctivitis may develop but are usually mild and selflimited. [4] After primary infection the virus is carried to the sensory ganglion establishing latent infection. Latent virus is incorporated in host DNA and cause periodical Subclinical reactivation, during which HSV is shed and patients are contagious. [4] A variety of stressors such as fever, hormonal change, ultraviolet radiation, trauma, or trigeminal injury may cause clinical reactivation, when the virus replicates and is transported in the sensory axons to the periphery. The pattern of disease depends on the site of reactivation, which may be remote from the site of primary disease. Hundreds of reactivations can occur during a lifetime. [4] A normal cornea is densely innervated, but lacks blood vessels. The chronic viral reactivations can lead to neurotrophic keratitis, a degenerative condition. Subsequent episodes not only damage nerves, leading to decreased corneal sensation (corneal hypoesthesia), but also lead to angiogenesis, and neovascularization. [5, 6] Decreased corneal sensation leads to loss of the corneal blink reflex. [5] This immunomediated reaction occurs as a result of cytokines released by CD4 + T cells. [7, 8, 9 ] SK on physical examination appears opaque or whitened, due to stromal infiltration. [10, 11] [12] Keratitis has also been shown to cause dryness in patients with stromal infection. [5] HSK lesions, which are immunoinflammatory in nature, can recur throughout life and often cause progressive corneal scaring resulting in visual impairment. [13] Current treatment involves broad local immunosuppression with topical steroids along with antiviral coverage. [13] While recurrent episodes of HSK can lead to stromal opacification, long-term use of antiviral drugs to prevent future episodes can increase the risk of resistance and toxicity. [14, 15, 16] Corticosteroids have significant side effects, and antivirals are only beneficial if replicating virus is present. [3] Acyclovir is not effective against the inflammatory stage of SK, as there is little virus to be found during peak inflammation. Since stromal response is immunomediated, steroids can help decrease recurrence, but they do not eliminate the virus. [17, 18] Immune regulatory drugs, such as cyclosporine A, present attractive alternatives to managing HSV stromal keratitis, given the immunemediated pathogenesis of stromal disease. [3] Cyclosporin is a lipophilic cyclic polypeptide which produces calcium-dependent, specific, reversible inhibition of transcription of interleukin-2 and several other cytokines, most notably in T helper lymphocytes. This reduces the production of a range of cytokines, inhibiting the activation and/or maturation of various cell types, including those involved in cell-mediated immunity. [19] Thus, cyclosporin has immunosuppressive properties and has been used successfully as a systemic immunomodulator for more than two decades, and numerous studies have investigated its mechanisms of action. In 2003 an ophthalmic formulation, cyclosporine 0.05% ophthalmic emulsion, was approved by the FDA to treat dry eye disease. Topical cyclosporine emulsion has also been investigated for treatment of other ocular surface disorders that may have an immune-based inflammatory component. In these trials, cyclosporine 0.05% ophthalmic emulsion has shown efficacy for management of posterior blepharitis, ocular rosacea, post-LASIK dry eye, contact lens intolerance, atopic keratoconjunctivitis, graft-versus-host disease, and herpetic stromal keratitis. As these disorders are often refractory to other available treatments, ophthalmic cyclosporine is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies. [20] In this study we evaluated the effect of 0.05% Cyclosporine(Restasis by Allergan,Hydroeyes by Lupin) on the patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical 1% prednisolone.
II. Material & Methods
This prospective case study clinical trial was conducted on 28 eyes of 28 patients attending the ophthalmology OPD of Rajindrahospital,Patiala from March 2016 to March 2017 who had herpes simplex virus non-necrotizing stromal keratitis and were unresponsive to topical 1% prednisolone treatment being given to them for atleast 6 weeks.Written informed consent was obtained from all patients and they were explained about the possible consequences. We interviewed the patient before hand to obtain information like personal data, contact number, any medical or ocular history, any history of drug allergy.
Inclusion Criteria 1. Patients unresponsive to topical 1%Prednisolone(a minimum of 6 weeks treatment)

Exclusion Criteria 1. Patients having corneal epithelial defect 2. Pregnant & Lactating mothers 3. Patients with Allergy to Cyclosporine
Age,Gender,affected eye were noted down.Best corrected visual acuity (BCVA) by Snellen's chart, Corneal sensation testing,IOP (measured by applanation tonometry)and detailed biomicroscopic anterior segment examinations were all done prior to the treatment. All patients were treated with topical 0.05% Cyclosporine as follows: 2 times a day of topical 0.05% Cyclosporine,in addition to the topical 1% Prednisolone(rapid tapering in 2 weeks)they were using for 15 days,and then 2 times a day of topical Cyclosporine 0.05% after topical 1% Prednisolone was discontinued. Visual acuity and slit-lamp appearance were evaluated every two weeks for at least three months.Intraocular pressure and corneal sensitivity were also examined routinely.28 eyes of 28 patients were included in the study,of these 16(57%)were male and 12(43%)were female.The average age of patients was 27.39±5.78years.Corneal haze was in right eye in 18 patients whereas 10 patients had it in their left eye.The average duration of topical 1% Prednisolone therapy was 1.6 months. BCVA(Best Corrected Visual Acuity)was assessed on Snellen's chart every 2 weeks IOP was measured at time of initiating the Cyclosporine drops,after 4 weeks and after 3 months of treatment. Corneal sensitivity was checked before initiating the Cyclosporine treatment and after 3 months of it. IOP value was significantly lowered in cases in which it had risen during treatment by prednisolone 1% eyedrops.It remained stable for next treatment period and no separate pressure lowering drug was required.No major adverse effect was noted except complaint of severe burning by 5 patients but it did not lead to discontinuation of the Cyclosporine eyedrops.Corneal sensitivity also improved after 3 months of cyclosporine therapy.Out of the 28 patients 4 had recurrence after 3 months of stopping the cyclosporine therapy,which was given for a period of 4-6 months.
II. Indentations and equations
III. Discussion
A study was conducted by Sanjay N.Rao,MD,University of Chicago,Chicago,Illinios and was presented at the American Academy of Ophthalmology Meeting, October 2004, in New Orleans, Louisiana To assess the efficacy of topical cyclosporine 0.05% (Restasis) in patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical prednisolone This series suggests that herpes simplex virus stromal keratitis can be treated effectively with topical cyclosporine, particularly in cases that are not responsive to topical prednisolone. [21] Another study titled Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis conducted byGündüz K. · Özdemir O. concluded that topical cyclosporin can be a valuable adjunct to acyclovir treatment in herpetic stromal keratitis. [22] A study titled Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Heiligenhaus A ,Steuhl KP suggests that HSV stromal keratitis can be treated successfully with CsAeyedrops, especially in non-necrotizing disease. CsA may be particularly helpful in the presence of steroid glaucoma, herpetic corneal ulcers, and to taper off topical corticosteroids. [23] Another study by Guang-Yong Qin,LiLiu,Xiang Wu of HuangshiAier Eye Hospital,Huangshi 435002,Hubei Province,Chinafrom January 2011 to January 2012concluded that For herpes simplex virus keratitis patients,usingcyclosporin A eye drops can be safe and effective,but the cure time is long. [24] An article titled Topical Ophthalmic Cyclosporine: Pharmacology And Clinical Uses by Dr.EricDonnenfeld stated that Topical cyclosporine emulsion has also been investigated for treatment of other ocular surface disorders that may have an immune-based inflammatory component. In these trials, cyclosporine 0.05% ophthalmic emulsion has shown efficacy for management of various diseases including herpetic stromal keratitis. And also ophthalmic cyclosporine is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies. [25] 
IV. Conclusion
By this series it can be suggested that herpes simplex virus stromal keratitis can be treated effectively with topical cyclosporine, particularly in cases refractory to topical prednisolone. and was not associated with any adverse effects.The small number of patients was the short coming of the study.
